Neuromuscular blocking agents are among the most commonly used drugs during general anesthesia. They compete with acetylcholine and interfere with the transmission of nerve impulses resulting in skeletal muscle relaxation. Based on their mechanism of action, neuromuscular blocking agents are classified as either depolarizing or nondepolarizing. Succinylcholine is a short-acting depolarizing agent. Commonly used nondepolarizing agents are curare (long-acting), pancuronium (long-acting), atracurium (intermediate-acting), and vecuronium (intermediate-acting). Neuromuscular blocking agents are used clinically to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery. This article provides an overview of the physiology of the neuromuscular transmission and summarizes our current knowledge on the use of these agents during general anesthesia.
Get full access to this article
View all access options for this article.
References
1.
GriffithHRJohnsonGE. The use of curare in general anesthesia. Anesthesiology1942; 3: 418–20.
2.
BevanDRBevanJCDonatiF. Muscle relaxants in clinical anesthesia. Chicago: Year Book Medical Publishers, 1988.
3.
StandaertFG. Release of transmitter at the neuromuscular junction. Br J Anaesth1982; 54: 131–45.
4.
FoldesFFChaudryIAKinkoMNagashimaH. Inhibition of mobilization of acetylcholine: The weak link in neuromuscular transmission during partial neuromuscular block with d-tubocurarine. Anesthesiology1989; 71: 218–23.
5.
PatonWDMWaudDR. The margin of safety of neuromuscular transmission. J Physiol (Lond)1967; 191: 59–90.
6.
WaudBEWaudDR. The margin of safety of neuromuscular transmission in the muscle of the diaphragm. Anesthesiology1972; 37: 417–22.
Viby-MogensenJ. Correlation of succinylcholine duration of action with plasma cholinesterase activity in subjects with the genotypically normal enzyme. Anesthesiology1980; 53: 517–20.
16.
SmithCELewisGDonatiFBevanDR. Dose-response relationship for succinylcholine in a patient with genetically determined low plasma cholinesterase activity. Anesthesiology1989; 70: 156–8.
17.
WhittakerM. Plasma cholinesterase variants and the anesthetist. Anaesthesia1980; 35: 174–97.
18.
GoldbergMELarijaniGEAzadSS, Comparison of tracheal intubating conditions and neuromuscular blocking profiles after intubating doses of mivacurium chloride or succinylcholine in surgical outpatients. Anesth Analg1989; 69: 93–9.
19.
ScottRPFGoatVA. Atracurium: Its speed of onset. A comparison with suxamethonium. Br J Anaesth1982; 54: 909–11.
20.
StirtJAKatzRLSchehlDLLeeC. Atracurium for intubation in man. A clinical and electromyographic study. Anaesthesia1984; 39: 1214–21.
21.
FaheyMRMorrisRBMillerRDSohnYJCronnellyRGencarelliP. Clinical pharmacology of ORG NC45 (Norcuron): A new nondepolarizing muscle relaxant. Anesthesiology1981; 55: 6–11.
22.
TullockWCDianaPCookDR, Neuromuscular and cardiovascular effects of high-dose vecuronium. Anesth Analg1990; 70: 86–90.
23.
BlackburnCLMorganM. Comparison of speed of onset of fazadinium, pancuronium, tubocurarine and suxamethonium. Br J Anaesth1978; 50: 361–4.
24.
LowryKGMirakhurRKLaveryGGClarkeRSJ. Vecuronium and atracurium in the elderly: A clinical comparison with pancuronium. Acta Anaesthesiol Scand1985; 29: 405–8.
25.
BaliIMDundeeJWDoggartJR. The source of increased plasma potassium following succinylcholine. Anesth Analg1975; 54: 680–6.
26.
BourkeDLRosenbergM. Changes in total serum Ca+ +, Na+, and K+ with administration of succinylcholine. Anesthesiology1978; 49: 361–3.
27.
TolmieJDJoyceTHMitchellGD. Succinylcholine danger in the burned patient. Anesthesiology1967; 28: 467–70.
28.
GronertGATheyeRA. Pathophysiology of hypercalcemia induced by succinylcholine. Anesthesiology1975; 43: 89–99.
29.
FeingoldAVelazquezJL. Suxamethonium infusion rate and observed fasciculations. A dose-response study. Br J Anaesth1979; 51: 241–5.
30.
HorrowJCLambertDH. The search for an optimal interval between pretreatment dose of d-tubocurarine and succinylcholine. Can Anaesth Soc J1984; 31: 528–33.
31.
PandeyKBadolaRPKumarS. Time course of intraocular hypertension produced by suxamethonium. Br J Anaesth1972; 44: 191–6.
32.
MintonMDGrosslightKStirtJABedfordRF. Increases in intracranial pressure from succinylcholine: Prevention by prior nondepolarizing blockade. Anesthesiology1986; 65: 165–9.
33.
DonlonJVSavareseJJAliHHTeplikRS. Human dose-response curves for neuromuscular blocking drugs: A comparison of two methods of construction and analysis. Anesthesiology1980; 53: 161–6.
34.
SavareseJJAliHHAntonioRP. The clinical pharmacology of metocurine: Dimethyltubocurarine revisited. Anesthesiology1977; 47: 277–84.
35.
GoudouzianNGDonlonJVSavareseJJRyanJF. Reevaluation of dosage and duration of action of d-tubocurarine in the pediatric age group. Anesthesiology1975; 43: 416–25.
36.
MatteoRSSpectorSHorowitzPE. Relation of serum d-tubocurarine concentration to neuromuscular blockade in man. Anesthesiology1974; 41: 440–3.
37.
MillerRDEgerEIIIWayWLStevensWCDolanWM. Comparative neuromuscular effects of forane and halothane alone and in combination with d-tubocurarine in man. Anesthesiology1971; 35: 38–42.
38.
StoeltingRKMcCammonRLHilgenbergJC. Changes in blood pressure with varying rates of administration of d-tubocurarine. Anesth Analg1980; 59: 697–9.
39.
MossJRosowCESavareseJJPhilbinDMKniffenKJ. Role of histamine in the hypotensive action of d-tubocurarine in humans. Anesthesiology1981; 55: 19–25.
40.
BastaSJSavareseJJAliHHMossJGionfriddoM. Histamine-releasing potencies of atracurium, dimethyl tubocurarine and tubocurarine. Br J Anaesth1983; 55 (suppl): 105S–6S.
41.
MillerRDMatteoRSBenetLZSohnYJ. The pharmacokinetics of d-tubocurarine in man with and without renal failure. J Pharmacol Exp Ther1977; 202: 1–7.
42.
MatteoRSNishitatenoKPuaEKSpectorS. Pharmacokinetics of d-tubocurarine in man: Effect of an osmotic diuretic or urinary excretion. Anesthesiology1980; 52: 335–8.
43.
RamzanMIShanksCATriggsEJ. Pharmacokinetics of tubocurarine administered by combined iv bolus and infusion. Br J Anaesth1980; 52: 893–9.
44.
FisherDMO'KeeffeCStanskiDRCronnellyRMillerRDGregoryGA. Pharmacokinetics and pharmacodynamics of d-tubocurarine in infants, children, and adults. Anesthesiology1982; 57: 203–8.
45.
StanskiDRHamJMillerRDSheinerLB. Pharmacokinetics and pharmacodynamics of d-tubocurarine during nitrous oxide-narcotic and halothane anesthesia in man. Anesthesiology1979; 51: 235–41.
46.
MatteoRSBrothertonWPNishitatenoKKhambattaHJDiasJ. Pharmacodynamics and pharmacokinetics of metocurine in humans: Comparison to d-tubocuraruine. Anesthesiology1982; 57: 183–90.
47.
HamJStanskiDRNewfieldPMillerRD. Pharmacokinetics and dynamics of d-tubocurarine during hypothermia in humans. Anesthesiology1981; 55: 631–5.
48.
MartynJAJMatteoRSGreenblattDJLebowitzPWSavareseJJ. Pharmacokinetics of d-tubocurarine in patients with thermal injury. Anesth Analg1982; 61: 241–6.
49.
MeijerDKFWeiteringJGVermeerGAScafAHJ. Comparative pharmacokinetics of d-tubocurarine and metocurine in man. Anesthesiology1979; 51: 402–7.
50.
McLeodKWatsonMJRawlinsMD. Pharmacokinetics of pancuronium in patients with normal and impaired renal function. Br J Anaesth1976; 48: 341–5.
51.
DuvaldestinPAgostonSHenzelDKerstenUWDesmontsJM. Pancuronium pharmacokinetics in patients with liver cirrhosis. Br J Anaesth1978; 50: 1131–6.
52.
SohnYJBenciniAFScafAHJKerstenUWAgostonS. Comparative pharmacokinetics and dynamics of vecuronium and pancuronium in anesthetized patients. Anesth Analg1986; 65: 233–9.
53.
SomogyiAAShanksCATriggsEJ. Disposition kinetics of pancuronium bromide in patients with total biliary obstruction. Br J Anaesth1977; 49: 1103–8.
54.
DuvaldestinPDemetriouMD'HollanderA. Pharmacokinetics of pancuronium in man: A linear system. Eur J Clin Pharmacol1982; 25: L369–72.
55.
CronnellyRFisherDMMillerRDGencarelliPNguyen-GruenkeLCastagnoliNJr. Pharmacokinetics and pharmacodynamics of vecuronium (ORG NC45) and pancuronium in anesthetized humans. Anesthesiology1983; 58: 405–8.
56.
RuppSMCastagnoliKPFisherDMMillerRD. Pancuronium and vecuronium pharmacokinetics and pharmacodynamics in younger and elderly adults. Anesthesiology1987; 67: 45–9.
57.
DuvaldestinPSaadaJBergenJLD'HollanderADesmontsJM. Pharmacokinetics, pharmacodynamics, and dose-response relationships of pancuronium in control and elderly subjects. Anesthesiology1982; 56: 36–40.
58.
FisherDMCastagnoliKMillerRD. Vecuronium kinetics and dynamics in anesthetized infants and children. Clin Pharmacol Ther1985; 37: 402–6.
59.
FaheyMRMorrisRBMillerRDNguyenTLUptonRA. Pharmacokinetics of ORG NC45 (norcuron) in patients with and without renal failure. Br J Anaesth1981; 53: 1049–53.
60.
LebraultCBergerJLD'HollanderAAGomeniRHenzelDDuvaldestinP. Pharmacokinetics and pharmacodynamics of vecuronium (ORG NC45) in patients with cirrhosis. Anesthesiology1985; 62: 601–5.
61.
LebraultCDuvaldestinPHenzelDChauvinMGuesnonP. Pharmacokinetics and pharmacodynamics of vecuronium in patients with cholestasis. Br J Anaesth1986; 58: 983–7.
62.
ArdenJRLynamDPCastagnoliKPCanfellPCCannonJCMillerRD. Vecuronium in alcoholic liver disease: A pharmacokinetic and pharmacodynamic analysis. Anesthesiology1988; 68: 771–6.
63.
BenciniAFScafAHJSohnYJ, Disposition and urinary excretion of vecuronium bromide in anesthetized patients with normal renal function or renal failure. Anesth Analg1986; 65: 245–51.
64.
HughesR. Atracurium: An overview. Br J Anaesth1986; 58 (suppl): 2S–5S.
65.
KittsJBFisherDMCanfellPC, Pharmacokinetics and pharmacodynamics of atracurium in the elderly. Anesthesiology1990; 72: 272–5.
66.
WardSBoheimerNWeatherleyBCSimmondsRJDopsonTA. Pharmacokinetics of atracurium and its metabolites in patients with normal renal function, and in patients in renal failure. Br J Anaesth1987; 59: 697–706.
67.
WardSNeillEAM. Pharmacokinetics of atracurium in acute hepatic failure (with acute renal failure). Br J Anaesth1983; 55: 1169–72.
68.
ParkerCJRHunterJM. Pharmacokinetics of atracurium and laudanosme in patients with hepatic cirrhosis. Br J Anaesth1989; 62: 177–83.
69.
KentAPParkerCJRHunterJM. Pharmacokinetics of atracurium and laudanosme in the elderly. Br J Anaesth1989; 63: 661–6.
70.
MatteoRSBackusWWMcDanielDDBrothertonWPAbrahamRDiazJ. Pharmacokinetics and pharmacodynamics of d-tubocurarine and metocurine in the elderly. Anesth Analg1985; 64: 23–9.
71.
GhoneimMMKramerEBannowRPandyaHRouthJI. Binding of d-tubocurarine to plasma proteins in normal man and in patients with hepatic or renal disease. Anesthesiology1973; 39: 410–5.
72.
DuvaldestinPHenzelD. Binding of tubocurarine, fazadinium, pancuronium and ORG NC45 to serum proteins in normal man and in patients with cirrhosis. Br J Anaesth1982; 54: 513–6.
73.
BairdWLMReidAM. The neuromuscular blocking properties of a new steroid compound, pancuronium bromide. A pilot study in man. Br J Anaesth1967; 39: 775–80.
74.
GramstadLLilleassenP. Neuromuscular blocking effects of atracurium, vecuronium and pancuronium during bolus and infusion administration. Br J Anaesth1985; 57: 1052–9.
75.
KriegNCrulJFBooijLHDJ. Relative potency of ORG NC 45, pancuronium, alcuronium and tubocurarine in anaesthetized man. Br J Anaesth1980; 52: 783–8.
76.
EngbaekJOrdingHViby-MogensenJ. Neuromuscular blocking effects of vecuronium and pancuronium during halothane anaesthesia. Br J Anaesth1983; 55: 497–500.
77.
KerrWJBairdWLM. Clinical studies on ORG NC45: Comparison with pancuronium. Br J Anesth1982; 54: 1159–65.
78.
MillerRDWayWLDolanWMStevensWCEgerEIII. Comparative neuromuscular effects of pancuronium, gallamine, and succinylcholine during forane and halothane anesthesia in man. Anesthesiology1971; 35: 509–14.
79.
MillerRDWayWLDolanWMStevensWCEgerEIII. The dependence of pancuronium and d-tubocurarine-induced neuromuscular blockade on alveolar concentrations of halothane and forane. Anesthesiology1972; 37: 573–81.
80.
MontgomeryCJStewardDJ. A comparative evaluation of intubating doses of atracurium, d-tubocurarine, pancuronium and vecuronium in children. Can J Anaesth1988; 35: 36–40.
81.
CashmanJNJonesRMVellaLM. Fade characteristics and onset times following administration of pancuronium, tubocurarine and a mixture of both agents. Br J Anaesth1985; 57: 488–492.
82.
StoeltingRK. The hemodynamic effects of pancuronium and d-tubocurarine in anesthetized patients. Anesthesiology1972; 36: 612–5.
83.
GregorettiSMSohnYJSiaRL. Heart rate and blood pressure changes after ORG NC45 (vecuronium) and pancuronium during halothane and enflurane anesthesia. Anesthesiology1982; 56: 392–5.
84.
EngbaekJOrdingHSorensenBViby-MogensenJ. Cardiac effects of vecuronium and pancuronium during halothane anaesthesia. Br J Anaesth1983; 55: 501–5.
85.
FerresCJCarsonIWLyonsSMOrrIAPattersonCCClarkeRSJ. Haemodynamic effects of vecuronium, pancuronium and atracurium in patients with coronary artery disease. Br J Anaesth1987; 59: 305–11.
86.
MorrisRBCahalanMKMillerRDWilkinsonPLQuashaALRobinsonSL. The cardiovascular effects of vecuronium (ORG NC45) and pancuronium in patients undergoing coronary artery bypass grafting. Anesthesiology1983; 58: 438–40.
87.
SalmenperaM.PeltolaKTakkunenOHeinonenJ. Cardiovascular effects of pancuronium and vecuronium during high-dose fentanyl anesthesia. Anesth Analg1983; 62: 1059–64.
88.
AgostonSVermeerGAKerstenUWMeijerKF. The fate of pancuronium bromide in man. Acta Anaesthesiol Scand1983; 17: 267–75.
89.
AgostonSCrulJFKerstenUNScafAHJ. Relationship of the serum concentration of pancuronium to its neuromuscular activity in man. Anesthesiology1977; 47: 509–12.
90.
McLeodKHullCJWatsonMJ. Effects of aging on the pharmacokinetics of pancuronium. Br J Anaesth1979; 51: 435–8.
91.
BerntmanLRosebergBSchweikhIYousefH. Atracurium and pancuronium in renal insufficiency. Acta Anesthesiol Scand1989; 33: 48–52.
92.
WoodMStoneWJWoodAJJ. Plasma binding of pancuronium: Effects of age, sex and disease. Anesth Analg1983; 62: 29–32.
93.
SavageDSSleighTCarlyleI. The emergence of ORG NC45, l-[2 β,3α,5α,16β,17β]-3, 17-bis (acetyloxy)-2-(l-piperidinyl)-androstan-16-YL]-l-methyl piperidinium bromide, from the pancuronium series. Br J Anaesth1980; 52 (suppl): 3S–9S.
94.
KriegNCrulJFBooijLHDJ. Relative potency of ORG NC45, pancuronium, atracuronium and tubocurarine in anaesthetized man. Br J Anaesth1980; 52: 783–8.
95.
O'HaraDRFragenRJShanksCA. The effects of age on the dose-response curves for vecuronium in adults. Anesthesiology1985; 63: 542–4.
96.
GramstadLLilleaasenP. Dose-response relation for atracurium, ORG NC45 and pancuronium. Br J Anaesth1982; 54: 647–51.
97.
CrulJFBooijLHDJ. First clinical experience with ORG NC45. Br J Anaesth1980; 52 (suppl): 49S–52S.
98.
MeistelmanCLooseJPSaint-MauriceCDelleurMMDasilvaGL. Clinical pharmacology of vecuronium in children. Studies during nitrous oxide and halothane in oxygen anaesthesia. Br J Anaesth1986; 58: 996–1000.
99.
AgostonSSaltPNewtonDBenciniABoomsmaPErdmannW. The neuromuscular blocking action of ORG NC45, a new pancuronium derivative, in anesthetized patients. A pilot study. Br J Anaesth1980; 52 (suppl): 53S–9S.
100.
CassonWRJonesRM. Vecuronium induced neuromuscular blockade. The effect of increasing dose on speed of onset. Anaesthesia1986; 41: 354–7.
101.
GinsbergBGlassPSQuillTShafronDOsseyKD. Onset and duration of neuromuscular blockade following high-dose vecuronium administration. Anesthesiology1989; 71: 201–5.
102.
GramstadLLilleaasenPMinsaasB. Onset time and duration of action for atracurium, ORG NC45 and pancuronium. Br J Anaesth1982; 54: 827–30.
103.
RuppSMMillerRDGencarelliPJ. Vecuronium-induced neuromuscular blockade during enflurane, isoflurane, and halothane anesthesia in humans. Anesthesiology1984; 60: 102–5.
104.
BastaSJSavareseJJAliHHSunderNMossJGionfriddoMEmbreeP. Vecuronium does not alter serum histamine within the clinical dose range (abstract). Anesthesiology1983; 59: A273.
105.
MarshallIGGibbAJDurantNN. Neuromuscular and vagal blocking actions of pancuronium bromide, its metabolites and vecuronium bromide (ORG NC45) and its potential metabolites in the anesthetized cat. Br J Anesth1983; 55: 703–13.
106.
BenciniAFScafAHJSohnYJKersten-KleefUWAgostonS. Hepatobiliary disposition of vecuronium bromide in man. Br J Anaesth1986; 58: 988–95.
107.
D'HollanderAMassauxFNevelsteenMAgostonS. Age-dependent dose-response relationship of ORG NC45 in anaesthetized patients. Br J Anaesth1982; 54: 653–7.
108.
KalliIMeretojaOA. Duration of action of vecuronium in infants and children anaesthetized without potent inhalation agents. Acta Anaesthesiol Scand1989; 33: 29–33.
109.
MeretojaOA. Is vecuronium a long-acting neuromuscular blocking agent in neonates and infants?Br J Anaesth1989; 62: 184–7.
110.
MerrettRAThompsonCWWebbFW. In vitro degradation of atracurium in human plasma. Br J Anaesth1983; 55: 61–6.
111.
NeillEAMChappleDJThompsonCW. Metabolism and kinetics of atracurium: An overview. Br J Anaesth1983; 55 (suppl): 23S–5S.
112.
HealyTEJPughNDKayBSivalingamTPettsHV. Atracurium and vecuronium: Effect of dose on the time of onset. Br J Anaesth1986; 58: 620–4.
113.
DebrosFMLaiAScottR, Pharmacokinetics and pharmacodynamics of atracurium during isoflurane anesthesia in normal and anephric patients. Anesth Analg1986; 65: 743–6.
114.
FisherDMCanfellPCFaheyMR, Elimination of atracurium in humans: Contribution of Hofmann elimination and ester hydrolysis versus organ-based elimination. Anesthesiology1986; 65: 6–12.
115.
TsuiDGrahamGGTordaTA. The pharmacokinetics of atracurium isomers in vitro and in humans. Anesthesiology1987; 67: 722–8.
116.
FoldesFFNagashimaHBorosMTassonyiEFitzalSAgostonS. Muscular relaxation with atracurium, vecuronium and duador under balanced anaesthesia. Br J Anaesth1983; 55 (suppl): 97S–103S.
117.
SokollMDGergisSDMehtaMAliNMLineberryC. Safety and efficacy of atracurium (BW 33A) in surgical patients receiving balanced or isoflurane anesthesia. Anesthesiology1983; 58: 450–5.
118.
D'HollanderAALuyckxCBarvisLDevilleA. Clinical evaluation of atracurium besylate requirement for a stable muscle relaxation during surgery: Lack of age related effects. Anesthesiology1983; 59: 237–40.
119.
BrandomBWRuddGDCookDR. Clinical pharmacology of atracurium in paediatric patients. Br J Anaesth1983; 55 (suppl): 117S–21S.
120.
BrandomBWCookDRWoelfelSKRuddGDFehrBLineberryGG. Atracurium infusion requirements in children during halothane, isoflurane, and narcotic anesthesia. Anesth Analg1985; 64: 471–6.
121.
RuppSMMcChristianJWMillerRD. Neuromuscular effects of atracurium during halothane-nitrous oxide and enflurane-nitrous oxide anesthesia in humans. Anesthesiology1985; 63: 16–19.
122.
StaunPErikssonLICederholmILennmarkenC. Clinical experience with atracurium during prolonged anesthesia. Anesth Intens Care1989; 17: 280–4.
123.
PayneJPHughesR. Evaluation of atracurium in anaesthetized man. Br J Anaesth1981; 53: 45–54.
124.
BastaSJAliHHSavareseJJ, Clinical pharmacology of atracurium besylate (BW334): A new non-depolarizing muscle relaxant. Anesth Analg1982; 61: 723–9.
125.
MirakhurRKLaveryGGClarkeRSJGibsonFMMcAteerE. Atracurium in clinical anaesthesia: Effect of dosage on onset, duration and conditions for tracheal intubation. Anaesthesia1985; 40: 801–5.
126.
GergisSDSokollMDMehtaMKemmotsuORuddGD. Intubation conditions after atracurium and suxamethonium. Br J Anaesth1983; 55 (suppl): 83S–6S.
127.
ScottRPFSavareseJJBastaSJ, Atracurium: Clinical strategies for preventing histamine release and attenuating the haemodynamic response. Br J Anaesth1985; 57: 550–3.
128.
ScottRPFSavareseJJBastaSJ, Clinical pharmacology of atracurium given in high doses. Br J Anaesth1986; 58: 834–8.
129.
RuppSMFaheyMRMillerRD. Neuromuscular and cardiovascular effects of atracurium during nitrous oxide-fentanyl and nitrous oxide-isoflurane anesthesia. Br J Anaesth1983; 55 (suppl): 67S–70S.
130.
HilgenbergJCStoeltingRK. Haemodynamic effects of atracurium in the presence of potent inhalation agents. Br J Anaesth1986; 58 (suppl): 70S–4S.
131.
WeatherleyBCWilliamsSGNeillEAM. Pharmacokinetics, pharmacodynamics and dose-response relationship of atracurium administered IV. Br J Anaesth1983; 55 (suppl): 39S–45S.
132.
FaheyMRRuppSMCanfellC, Effect of renal failure on laudanosme excretion in man. Br J Anaesth1985; 57: 1049–51.
133.
WardSWeatherleyBC. Pharmacokinetics of atracurium and its metabolites. Br J Anaesth1986; 58 (suppl): 6S–10S.
134.
MillerRD. Pharmacokinetics of atracurium and other nondepolarizing neuromuscular blocking agents in normal patients and those with renal or hepatic dysfunction. Br J Anaesth1986; 58 (suppl): 11S–3S.
135.
BentleyJBBorealJDVaughanRWGandolfiAJ. Weight, pseudocholinesterase activity, and succinylcholine requirement. Anesthesiology1982; 57: 48–9.
136.
MartynJAJSzyfelbeinSKAliHHMatteoRSSavareseJJ. Increased d-tubocurarine requirement following major thermal injury. Anesthesiology1980; 52: 352–5.
137.
MillsAKMartynJAJ. Neuromuscular blockade with vecuronium in paediatric patients with burn injury. Br J Clin Pharmacol1989; 28: 155–9.
